FY2030 Earnings Estimate for TARS Issued By HC Wainwright

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Stock analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Tarsus Pharmaceuticals in a research note issued to investors on Tuesday, February 24th. HC Wainwright analyst M. Caufield expects that the company will earn $6.36 per share for the year. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The firm had revenue of $151.67 million during the quarter, compared to the consensus estimate of $144.56 million.

A number of other equities research analysts have also recently issued reports on the stock. Wall Street Zen raised shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Oppenheimer boosted their price target on shares of Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday. Zacks Research upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 23rd. Mizuho assumed coverage on Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They set an “outperform” rating and a $100.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $87.00.

Tarsus Pharmaceuticals Stock Up 4.4%

Shares of NASDAQ TARS opened at $75.87 on Wednesday. The stock has a market capitalization of $3.23 billion, a P/E ratio of -46.83, a PEG ratio of 1.05 and a beta of 0.57. Tarsus Pharmaceuticals has a one year low of $38.51 and a one year high of $85.25. The firm’s 50 day simple moving average is $72.12 and its two-hundred day simple moving average is $68.43. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.85 and a quick ratio of 4.25.

Institutional Trading of Tarsus Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Jennison Associates LLC raised its position in shares of Tarsus Pharmaceuticals by 5.5% in the 3rd quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock worth $154,790,000 after purchasing an additional 136,582 shares during the last quarter. TFG Asset Management GP Ltd increased its position in shares of Tarsus Pharmaceuticals by 40.1% during the 2nd quarter. TFG Asset Management GP Ltd now owns 250,000 shares of the company’s stock valued at $10,128,000 after purchasing an additional 71,530 shares during the last quarter. Capricorn Fund Managers Ltd bought a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter worth approximately $14,264,000. TimesSquare Capital Management LLC purchased a new position in shares of Tarsus Pharmaceuticals during the 3rd quarter worth $15,898,000. Finally, Allianz Asset Management GmbH purchased a new stake in Tarsus Pharmaceuticals in the second quarter worth about $227,000. Institutional investors own 90.01% of the company’s stock.

Insider Activity at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total transaction of $495,060.00. Following the completion of the transaction, the chief executive officer owned 857,991 shares in the company, valued at $70,792,837.41. This represents a 0.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Dianne C. Whitfield sold 7,397 shares of the business’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total transaction of $592,499.70. Following the transaction, the insider directly owned 38,958 shares in the company, valued at approximately $3,120,535.80. The trade was a 15.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 8.97% of the stock is currently owned by insiders.

Tarsus Pharmaceuticals News Summary

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Oppenheimer raised its price target materially and reiterated a positive stance (Outperform), which supports upside expectations for the shares. Oppenheimer Raises PT
• Positive Sentiment: Guggenheim raised its price target on TARS to $90 and maintained a Buy rating, providing additional analyst-level backing for further gains. Guggenheim PT $90
• Positive Sentiment: Tarsus announced management will participate in upcoming investor conferences—this increases management access to investors and can help sustain the re-rating momentum if management delivers encouraging updates. Investor Conferences
• Neutral Sentiment: A market commentary questioned whether Tarsus has been re-rated too cautiously following XDEMVY adoption headlines; this article frames debate about valuation vs execution but does not add hard fundamentals. Market Rerate Analysis
• Negative Sentiment: HC Wainwright trimmed multiple near-term and multi-year EPS forecasts in its Feb. 24 research note — lowering Q1 2026 to about ($0.42) (from $0.05), Q2 to ~($0.17) (from $0.09), Q3 to ~($0.07) (from $0.18), and cutting Q4/QFY and FY2027–FY2029 targets (e.g., FY2027 to $2.33 from $2.90, FY2028 to $3.10 from $4.26, FY2029 to $4.68 from $5.87). These downward revisions increase short-term earnings uncertainty and weigh on fundamental expectations.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.